{
    "ticker": "FDMT",
    "name": "Frequency Therapeutics, Inc.",
    "description": "Frequency Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments to restore hearing and address neurodegenerative diseases. Founded in 2014, the company employs its proprietary FX-322 platform technology, which leverages the body's innate ability to regenerate tissue. Frequency Therapeutics is primarily known for its lead product candidate, FX-322, designed to regenerate sensory hair cells in the cochlea of the inner ear to restore hearing in patients with sensorineural hearing loss. The company\u2019s mission is to transform the lives of individuals impacted by hearing loss and other degenerative conditions through groundbreaking therapies. By harnessing the power of small molecules to activate progenitor cells, Frequency aims to create a new class of regenerative medicine that can potentially reverse damage rather than merely treating symptoms. The company is committed to advancing its clinical programs with the hope of bringing these revolutionary therapies to market, thus paving the way for a future where hearing loss can be effectively treated.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Woburn, Massachusetts, USA",
    "founded": "2014",
    "website": "https://www.frequencytx.com",
    "ceo": "Chief Executive Officer",
    "social_media": {
        "twitter": "https://twitter.com/FrequencyTx",
        "linkedin": "https://www.linkedin.com/company/frequency-therapeutics/"
    },
    "investor_relations": "https://investors.frequencytx.com",
    "key_executives": [
        {
            "name": "Chief Executive Officer",
            "position": "CEO"
        },
        {
            "name": "David L. Lucchino",
            "position": "Co-Founder and CEO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "FX-322"
            ]
        }
    ],
    "seo": {
        "meta_title": "Frequency Therapeutics, Inc. | Regenerative Medicine for Hearing Loss",
        "meta_description": "Explore Frequency Therapeutics, Inc., a leader in biotechnology focused on restoring hearing and addressing neurodegenerative diseases with innovative therapies.",
        "keywords": [
            "Frequency Therapeutics",
            "Biotechnology",
            "Hearing Loss",
            "Regenerative Medicine",
            "FX-322"
        ]
    },
    "faq": [
        {
            "question": "What is Frequency Therapeutics known for?",
            "answer": "Frequency Therapeutics is known for developing innovative therapies to restore hearing and treat neurodegenerative diseases."
        },
        {
            "question": "What is FX-322?",
            "answer": "FX-322 is a product candidate designed to regenerate sensory hair cells in the inner ear to restore hearing."
        },
        {
            "question": "Where is Frequency Therapeutics headquartered?",
            "answer": "Frequency Therapeutics is headquartered in Woburn, Massachusetts, USA."
        },
        {
            "question": "When was Frequency Therapeutics founded?",
            "answer": "Frequency Therapeutics was founded in 2014."
        }
    ],
    "competitors": [
        "GNUS",
        "AVGR",
        "HEAR"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "REGN"
    ]
}